Edwards Lifesciences Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is ...

The Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA transcatheter heart valve system is indicated for use in patients with heart disease due to native calcific aortic stenosis at any ...

Edwards Lifesciences' Sapien 3 is actually already on the market—it received FDA approval in June 2015 for use in high-risk patients with severe, symptomatic aortic stenosis. But another indication is ...

TAVR Holds Potential: In the past few quarters, TAVR sales have been driven by the strong performance of the Edwards SAPIEN 3 Ultra valve in the United States, Europe and the Rest of the World ...

In Europe, the company continues its introduction of the SAPIEN 3 Ultra RESILIA valve and continues to be pleased with the exceptional patient outcomes. Additionally, Edwards received CE Mark ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

Global sales of the aortic valves, which are Edwards’ biggest product ... and the rollout of the Sapien 3 Ultra Resilia ...

Investigators reported superior outcome for women receiving the Edwards SAPIEN 3 or SAPIEN 3 Ultra Valves as compared to those receiving surgical aortic valve replacement for the primary endpoints ...

Edwards Lifesciences Corporation EW is ... However, the launch of the SAPIEN 3 Ultra RESILIA valve in Europe in May 2024 might have contributed to TAVR sales in the third quarter.

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its ...

Over the past few quarters, it has been observed that TAVR sales have been driven by the strong performance of the Edwards SAPIEN 3 Ultra valve in the United States, Europe and the Rest of the ...